Additional Relevant Details The results of a Phase 3 ALEX study of Alecensa (alectinib) are expected in 2017 (study projected to complete March).  Alecensa was recently approved in the US and Roche is currently seeking approval for the drug in Japan.  Results from this study as well as positive results from Phase 2 studies will be used for the regulatory filing.